Search PubMed⌕ Search
Home/Archive/PubMed

PubMed · 10172753

A method evaluation decision chart (MEDx chart) for judging method performance.

J O Westgard
View original source ↗Export metadata ↓

Abstract

OBJECTIVE: To introduce a new graphical tool that improves the process of making decisions about method performance. DATA SOURCES: Scientific literature, mathematical models, and the author's experience. STUDY SELECTION: Not applicable. DATA EXTRACTION: Not applicable. DATA SYNTHESIS: Relationship to charts of operating specifications (OPSpecs charts) provides guidance for classification of performance as poor, marginal, good, or excellent. CONCLUSION: Objective decisions on the performance of methods can be made quickly and easily with the aid of a Method Evaluation Decision Chart.

Explore related subjects

BiasClinical Laboratory TechniquesDecision TreesEvaluation Studies as TopicHumansQuality ControlJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

J O Westgard. A method evaluation decision chart (MEDx chart) for judging method performance.. https://pubmed.ncbi.nlm.nih.gov/10172753/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2026

Assessment of blinding in pharmacotherapy and noninvasive neuromodulation randomized controlled trials for neuropathic pain in adults.

In randomized controlled trials (RCTs), study participants and research personnel are often blinded to minimize biases related to knowing treatment allocation. To determine if blinding was effective, participants may be asked which treatment they believe they received ("treatment guess"). This descriptive review characterized blinding assessment (BA) reporting in pharmacotherapy and neuromodulation neuropathic pain RCTs. Of 288 papers, 36 (12.5%) reported a BA. One paper reported the results of 2 studies, so in total 37 studies with a BA were assessed. Of these, 19 were crossover, 17 parallel, and 1 partial crossover in design. All 37 studies assessed participant blinding, and 10 also assessed investigator blinding. Approximately 27% included an "unsure" answer option for treatment guess, and 38% asked the reason for the guess. There were no clear patterns in BA reporting across time nor based on treatment type. Seventeen trials provided sufficient data to calculate Bang Blinding Index (BI) to determine blinding success. Participants remained blinded (BI = 0 &#xb1; 0.2) in 10/17 placebo and 10/17 treatment arms, 6 placebo and 5 treatment arms had a BI > 0.2 suggesting possible unblinding, whereas 1 placebo and 2 treatment arms had a BI < -0.2 suggesting misinformed guessing. Overall, we found that BAs are done in a minority of published neuropathic pain trials and with variable methodology. Given the importance of minimizing risk of bias because of treatment unblinding, future studies should consider including BAs, and further consensus building is necessary to determine if and how BAs should be conducted and interpreted in analgesic clinical trials.

Bias↗